RxDoctor Payments Data

David Darr, MD

Family Medicine · Warsaw, INNPI 1447293402

Payments from drug & device makers

$8,601in general payments, 2019–2025

Across 556 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$753
  • Pfizer$592
  • Lilly USA, LLC$478
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$450
  • AstraZeneca$434
  • plus $4K from 52 others

What the payments were for

  • Speaking & faculty fees$1602%
  • Food & beverage$8,41398%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)128$1,433
Novo Nordisk54$753
Pfizer40$592
Lilly USA, LLC35$478
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)25$450
AstraZeneca23$434
Inspire Medical Systems, Inc.7$255
Axsome Therapeutics, Inc.13$238
Amgen17$225
Boehringer Ingelheim13$221
Shield Therapeutics Inc6$217
Kowa Pharmaceuticals America, Inc.16$205
Johnson & Johnson13$177
Astellas Pharma US Inc9$176
Sunovion Pharmaceuticals Inc.10$148
Sanofi2$145
Novartis9$145
Abbott7$133
Sumitomo Pharma America, Inc.8$132
Otsuka America Pharmaceutical, Inc.7$127
Exact Sciences8$124
Amarin Pharma, Inc.8$123
Biohaven Pharmaceuticals, Inc.3$110
Antares Pharma, Inc.6$103
Bayer7$100
Vanda Pharmaceuticals Inc.3$91
Mylan Specialty L.p.5$85
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$83
Takeda Pharmaceuticals U.S.A., Inc.6$82
Supernus Pharmaceuticals, Inc.4$72
Biohaven Pharmaceutical Holding Company Ltd.3$67
Esperion Therapeutics, Inc.4$58
Paratek Pharmaceuticals, Inc.3$56
Eisai Inc.4$55
Neurocrine Biosciences, Inc.3$54
Jazz Pharmaceuticals Inc.3$50
Sanofi-aventis U.S. LLC3$49
Mayne Pharma Commercial LLC2$47
Almatica Pharma LLC3$46
Corium, LLC3$46
Dexcom, Inc.3$45
Merck3$44
Lundbeck LLC2$38
Organon2$30
Phathom Pharmaceuticals, Inc.2$29
Idorsia Pharmaceuticals US Inc2$29
Xeris Pharmaceuticals, Inc.2$28
GSK2$26
Insulet Corporation1$21
Medtronic1$17
AMAG Pharmaceuticals, Inc.1$17
Avanir Pharmaceuticals, Inc.1$17
UCB, Inc.1$15
Amneal Pharmaceuticals LLC1$15
Ironshore Pharmaceuticals Inc.1$13
Arbor Pharmaceuticals, Inc.1$12
E.r. Squibb & Sons, L.L.C.1$11
Dermira, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,601 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$94,998
Medicare patients
245
Services billed
1,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin233$230,772
OzempicSemaglutide179$220,530
MounjaroTirzepatide123$158,307
RybelsusSemaglutide120$154,437
FarxigaDapagliflozin Propanediol144$129,113
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$94,839
EliquisApixaban97$86,401
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$40,441
ProliaDenosumab23$39,697
GemtesaVibegron50$38,403
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$33,732
MyrbetriqMirabegron61$30,923
Breo ElliptaFluticasone/Vilanterol36$24,304
XareltoRivaroxaban25$20,079
TrulicityDulaglutide16$17,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$753$374,967299 claims
Boehringer IngelheimJardiance$221$230,772233 claims
Lilly USA, LLCMounjaro, Trulicity$478$176,223139 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$434$172,593221 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$26$159,584178 claims
PfizerEliquis$592$86,40197 claims
AmgenProlia$225$39,69723 claims
Sumitomo Pharma America, Inc.Gemtesa$132$38,40350 claims
Astellas Pharma US IncMyrbetriq$176$30,92361 claims
MerckJanuvia, Belsomra$44$24,49731 claims
Johnson & JohnsonXarelto$177$20,07925 claims
AbbVieLinzess$1,433$15,25413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →